FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2925186318> ?p ?o ?g. }

• W2925186318 endingPage "222.e5" @default.
• W2925186318 startingPage "216" @default.
• W2925186318 abstract "Introduction The objective of the study was to determine whether sarcopenia is associated with pathologic and survival outcomes for patients with muscle-invasive bladder cancer (MIBC) treated with neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC). Patients and Methods We identified MIBC patients treated with cisplatin-based NAC in our cystectomy registry from 2000 to 2016. Pre- and post-NAC computed tomography images were analyzed with BodyCompSlicer, a validated body composition assessment tool. Sarcopenia was defined as a skeletal muscle index (SMI) below sex-specific international consensus values. Associations of clinical features with pathologic downstaging (<ypT2), major (Clavien III-V) complications, and cancer-specific mortality (CSM) were modeled using multivariable logistic and Cox proportional hazard regression models. Results A total of 183 patients were identified. Median follow-up was 3.0 years (interquartile range, 1.8-5.0), during which time 79 patients died, including 62 of bladder cancer. SMI declined by a median of 8.4% during NAC treatment. In multivariable logistic regression, neither pretreatment sarcopenia nor the amount of muscle mass loss during NAC was associated with downstaging to <ypT2 disease (P > .05). Meanwhile, only post-NAC sarcopenia (hazard ratio, 1.90; 95% confidence interval, 1.02-3.56; P = .04) was independently associated with an increased risk of CSM. Conclusion Sarcopenia after NAC and before RC appeared to be prognostic. Although skeletal muscle mass declined significantly during NAC, neither the degree of muscle loss nor pretreatment SMI were significantly associated with downstaging after NAC and RC. These data do not support the use of sarcopenia as a risk stratification tool for selection of patients for or monitoring response to NAC." @default.
• W2925186318 created "2019-04-01" @default.
• W2925186318 creator A5000171823 @default.
• W2925186318 creator A5005104565 @default.
• W2925186318 creator A5029672982 @default.
• W2925186318 creator A5042110752 @default.
• W2925186318 creator A5050135720 @default.
• W2925186318 creator A5066721028 @default.
• W2925186318 creator A5069162638 @default.
• W2925186318 creator A5077644150 @default.
• W2925186318 creator A5082725102 @default.
• W2925186318 creator A5087072211 @default.
• W2925186318 date "2019-06-01" @default.
• W2925186318 modified "2023-09-26" @default.
• W2925186318 title "Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer" @default.
• W2925186318 cites W1526907219 @default.
• W2925186318 cites W1828448189 @default.
• W2925186318 cites W1975918912 @default.
• W2925186318 cites W1981568481 @default.
• W2925186318 cites W2048967731 @default.
• W2925186318 cites W2096998881 @default.
• W2925186318 cites W2101398993 @default.
• W2925186318 cites W2103257412 @default.
• W2925186318 cites W2138012707 @default.
• W2925186318 cites W2145280166 @default.
• W2925186318 cites W2150919775 @default.
• W2925186318 cites W2166453367 @default.
• W2925186318 cites W2184087537 @default.
• W2925186318 cites W2208547614 @default.
• W2925186318 cites W2312081744 @default.
• W2925186318 cites W2582996716 @default.
• W2925186318 cites W2604335847 @default.
• W2925186318 cites W2604535399 @default.
• W2925186318 cites W2616760474 @default.
• W2925186318 cites W2619249519 @default.
• W2925186318 cites W2787431611 @default.
• W2925186318 cites W2789666761 @default.
• W2925186318 cites W2791650955 @default.
• W2925186318 cites W2802732717 @default.
• W2925186318 cites W2888969259 @default.
• W2925186318 cites W2892569203 @default.
• W2925186318 doi "https://doi.org/10.1016/j.clgc.2019.03.007" @default.
• W2925186318 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31060857" @default.
• W2925186318 hasPublicationYear "2019" @default.
• W2925186318 type Work @default.
• W2925186318 sameAs 2925186318 @default.
• W2925186318 citedByCount "20" @default.
• W2925186318 countsByYear W29251863182020 @default.
• W2925186318 countsByYear W29251863182021 @default.
• W2925186318 countsByYear W29251863182022 @default.
• W2925186318 countsByYear W29251863182023 @default.
• W2925186318 crossrefType "journal-article" @default.
• W2925186318 hasAuthorship W2925186318A5000171823 @default.
• W2925186318 hasAuthorship W2925186318A5005104565 @default.
• W2925186318 hasAuthorship W2925186318A5029672982 @default.
• W2925186318 hasAuthorship W2925186318A5042110752 @default.
• W2925186318 hasAuthorship W2925186318A5050135720 @default.
• W2925186318 hasAuthorship W2925186318A5066721028 @default.
• W2925186318 hasAuthorship W2925186318A5069162638 @default.
• W2925186318 hasAuthorship W2925186318A5077644150 @default.
• W2925186318 hasAuthorship W2925186318A5082725102 @default.
• W2925186318 hasAuthorship W2925186318A5087072211 @default.
• W2925186318 hasConcept C119060515 @default.
• W2925186318 hasConcept C121608353 @default.
• W2925186318 hasConcept C126322002 @default.
• W2925186318 hasConcept C126894567 @default.
• W2925186318 hasConcept C143998085 @default.
• W2925186318 hasConcept C207103383 @default.
• W2925186318 hasConcept C2775910329 @default.
• W2925186318 hasConcept C2776214593 @default.
• W2925186318 hasConcept C2776694085 @default.
• W2925186318 hasConcept C2780352672 @default.
• W2925186318 hasConcept C44249647 @default.
• W2925186318 hasConcept C50382708 @default.
• W2925186318 hasConcept C71924100 @default.
• W2925186318 hasConceptScore W2925186318C119060515 @default.
• W2925186318 hasConceptScore W2925186318C121608353 @default.
• W2925186318 hasConceptScore W2925186318C126322002 @default.
• W2925186318 hasConceptScore W2925186318C126894567 @default.
• W2925186318 hasConceptScore W2925186318C143998085 @default.
• W2925186318 hasConceptScore W2925186318C207103383 @default.
• W2925186318 hasConceptScore W2925186318C2775910329 @default.
• W2925186318 hasConceptScore W2925186318C2776214593 @default.
• W2925186318 hasConceptScore W2925186318C2776694085 @default.
• W2925186318 hasConceptScore W2925186318C2780352672 @default.
• W2925186318 hasConceptScore W2925186318C44249647 @default.
• W2925186318 hasConceptScore W2925186318C50382708 @default.
• W2925186318 hasConceptScore W2925186318C71924100 @default.
• W2925186318 hasFunder F4320337472 @default.
• W2925186318 hasIssue "3" @default.
• W2925186318 hasLocation W29251863181 @default.
• W2925186318 hasLocation W29251863182 @default.
• W2925186318 hasOpenAccess W2925186318 @default.
• W2925186318 hasPrimaryLocation W29251863181 @default.
• W2925186318 hasRelatedWork W1562998603 @default.
• W2925186318 hasRelatedWork W2022837219 @default.
• W2925186318 hasRelatedWork W2053563036 @default.
• W2925186318 hasRelatedWork W2599105519 @default.

• next